Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (141-150 of 238) with videos related to

Pageof 24
Sort By:
British Journal of Clinical Pharmacology|August 9, 2021
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonistMartine Gehin, Jolanta Wierdak, Giancarlo Sabattini, et al.
Antiviral Therapy|April 14, 2010
Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participantsJasper Dingemanse, Paul L M van Giersbergen, Alain Patat, et al.
British Journal of Clinical Pharmacology|April 19, 2013
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human studyPatrick Brossard, Hartmut Derendorf, Jian Xu, et al.
British Journal of Clinical Pharmacology|June 26, 2014
Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjectsPatricia N Sidharta, Paul L M van Giersbergen, Michael Wolzt, et al.
Clinical Pharmacokinetics|April 13, 2017
Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1Anke-Katrin Volz, Andreas Krause, Walter Emil Haefeli, et al.
European Journal of Clinical Pharmacology|May 5, 2011
Macitentan: entry-into-humans study with a new endothelin receptor antagonistPatricia N Sidharta, Paul L M van Giersbergen, Atef Halabi, et al.
Pharmacology|February 4, 2012
Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjectsMatthias Hoch, Petra Hoever, Jochen Zisowsky, et al.
CNS Drugs|November 18, 2020
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy SubjectsBenjamin Berger, Sander Brooks, Rob Zuiker, et al.
Clinical and Translational Science|April 21, 2019
Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of ClazosentanPierre-Eric Juif, Christine Voors-Pette, Mike Ufer, et al.
Pharmacology Research & Perspectives|October 6, 2023
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjectsBenjamin Berger, Priska Kaufmann, Matthias Berse, et al.
Pageof 24

Showing results (141-150 of 238) with videos related to

Sort By:
Pageof 24
British Journal of Clinical Pharmacology|August 9, 2021
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonistMartine Gehin, Jolanta Wierdak, Giancarlo Sabattini, et al.
Antiviral Therapy|April 14, 2010
Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participantsJasper Dingemanse, Paul L M van Giersbergen, Alain Patat, et al.
British Journal of Clinical Pharmacology|April 19, 2013
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human studyPatrick Brossard, Hartmut Derendorf, Jian Xu, et al.
British Journal of Clinical Pharmacology|June 26, 2014
Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjectsPatricia N Sidharta, Paul L M van Giersbergen, Michael Wolzt, et al.
Clinical Pharmacokinetics|April 13, 2017
Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1Anke-Katrin Volz, Andreas Krause, Walter Emil Haefeli, et al.
European Journal of Clinical Pharmacology|May 5, 2011
Macitentan: entry-into-humans study with a new endothelin receptor antagonistPatricia N Sidharta, Paul L M van Giersbergen, Atef Halabi, et al.
Pharmacology|February 4, 2012
Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjectsMatthias Hoch, Petra Hoever, Jochen Zisowsky, et al.
CNS Drugs|November 18, 2020
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy SubjectsBenjamin Berger, Sander Brooks, Rob Zuiker, et al.
Clinical and Translational Science|April 21, 2019
Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of ClazosentanPierre-Eric Juif, Christine Voors-Pette, Mike Ufer, et al.
Pharmacology Research & Perspectives|October 6, 2023
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjectsBenjamin Berger, Priska Kaufmann, Matthias Berse, et al.
Pageof 24